World Pharma News

Syndicate content
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharm
Updated: 11 hours 52 min ago

Antidepressant use in people with both physical health problems and depression

Fri, 09/08/2023 - 10:00
Many people with diseases such as cancer or diabetes or those who have had a heart attack or stroke also suffer from depression. How effective are antidepressants for these patients? And are they just as safe for these people as for those without physical health problems? Researchers from Charité - Universitätsmedizin Berlin and Aarhus University in Denmark have teamed up to investigate these questions.

A free online tool can help prostate cancer patients save on out-of-pocket drug costs

Thu, 09/07/2023 - 10:00
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds.

For patients enrolled in Medicare Part D prescription drug plans, out of pocket costs can vary significantly. But by using an online Medicare plan finder tool, patients can compare pricing among all Part D drug plans offered in their area and select the most affordable plan.

Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer

Wed, 09/06/2023 - 10:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

First-in-class targeted microRNA therapy slows cancer tumor growth

Tue, 09/05/2023 - 10:00
A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated with the new therapy did not increase in size over the course of a 21-day study, while untreated tumors tripled in size over the same time period.

Cancer can begin almost anywhere in the human body. It is characterized by cells that divide uncontrollably and that may be able to ignore signals to die or stop dividing, and even evade the immune system.

Why breast cancer survivors don't take their medication, and what can be done

Mon, 09/04/2023 - 10:00
For roughly 80% of breast cancer survivors, treatment doesn’t end with surgery, radiation and chemotherapy. Instead, for the next five to 10 years, doctors recommend that they take medication to block sex hormones, which can fuel tumor growth and spark recurrence.

The drugs are life-saving: They've been shown to cut risk of cancer recurrence by as much as half in patients with hormone receptor-positive tumors (HR+) - the most common form of breast cancer.

Statins linked to lower risk of colorectal cancer in patients with ulcerative colitis

Fri, 09/01/2023 - 10:00
Cholesterol-lowering statins might protect patients with ulcerative colitis from developing and dying from colorectal cancer. Statin treatment was also associated with a lower risk of death regardless of cause in patients with ulcerative colitis or Crohn's disease. This is according to a study by researchers at Karolinska Institutet in Sweden published in eClinicalMedicine.

How Unique Immune Cells can Recognize - and destroy - Tumors

Thu, 08/31/2023 - 10:00
Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells. Cancer patients with higher levels of these T cells in their tumors tend to fare better than those with lower levels. But scientists have struggled to understand exactly how gamma delta T cells can recognize cancerous cells, and how new cancer therapies may be able to take advantage of these powerful immune cells.

BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint

Wed, 08/30/2023 - 10:00
Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.

Drug that targets scar-like tissue in tumours shows promise for aggressive pancreatic cancer

Tue, 08/29/2023 - 10:00
Findings from the Garvan Institute of Medical Research reveal a new Australian drug that targets scar-like 'fibrotic' tissue within tumours shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer with a five-year survival rate of less than 10%.

The research in mouse models showed that when given in combination with chemotherapy, the drug PXS-5505 increased survival time by more than 35%, compared to chemotherapy treatment alone.

Novartis completes acquisition of Chinook Therapeutics

Mon, 08/28/2023 - 10:00
Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.

New 'promising medicines' fund may incentivise commercialisation of high price drugs with weak evidence on clinical benefits

Fri, 08/25/2023 - 10:00
A new fund to fast-track patient access to potentially valuable new medicines may incentivise the pharmaceutical industry to develop high priced drugs for rare diseases with weak evidence on clinical benefits.

Health economics and policy academics from the London School of Hygiene & Tropical Medicine (LSHTM), writing in the Journal of the Royal Society of Medicine, warn that if the NHS England Innovative Medicines Fund (IMF) is not implemented appropriately, it risks disincentivising the generation of essential evidence and could shift the financial burden from the pharmaceutical industry to the public finances.

Researchers decode new antibiotic

Thu, 08/24/2023 - 10:00
More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the world are searching for new effective substances. Researchers from the University of Bonn, the German Center for Infection Research (DZIF), Utrecht University (Netherlands), Northeastern University in Boston (USA) and the company NovoBiotic Pharmaceuticals in Cambridge (USA) now have discovered and deciphered the mode of action of a new antibiotic.

U.S. FDA Approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in infants through active immunization of pregnant individuals 32-36 weeks of gestational age

Wed, 08/23/2023 - 10:00
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.

Mahana Therapeutics signs agreement with Consumer Health division of Bayer to commercialize digital therapeutics

Tue, 08/22/2023 - 10:00
Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer to commercialize digital therapeutics. Earlier this year, Bayer announced the launch of a new business unit focused on delivering new digitally enabled precision health products to market.

DNA repair discoveries hold promise for new approaches to cancer treatment

Mon, 08/21/2023 - 10:00
DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive. In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.

Most cells rely on a system called homologous recombination or HR, which uses proteins called BRCA1 and BRCA2 for accurate DNA repair.

AbbVie announces European Commission approval of AQUIPTA® (atogepant) for the preventive treatment of migraine in adults

Fri, 08/18/2023 - 10:00
AbbVie (NYSE: ABBV) announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

Adherence to a Mediterranean lifestyle associated with lower risk of all-cause and cancer mortality

Thu, 08/17/2023 - 10:00
People who adhere to a Mediterranean lifestyle - which includes a diet rich in fruits, vegetables, and whole grains; healthy eating habits like limiting added salts and sugars; and habits promoting adequate rest, physical activity, and socialization - have a lower risk of all-cause and cancer mortality, according to a new study led by La Universidad Autónoma de Madrid and Harvard T.H. Chan School of Public Health.